Intriguingly, although KRAS mutations are reported for 99% of PanIN-1s37, no more than 95% of pancreatic cancers have a KRAS or BRAF mutation, supporting the notion that a KRAS mutation is not strictly required for the development of pancreatic cancer [22]. This evidence concerns the gene KRAS and pancreatic neoplasm.